Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
Responders achieved weight loss and improvements in physical function
Original title: “Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial”
The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.
Original title: “Lilly to invest extra $4.5B across Indiana manufacturing”
Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.
Original title: “Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site”
With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.
Original title: “GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist”
In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.
Original title: “Novo hikes guidance on Wegovy pill’s fast sales start”
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past expectations by 86%.
Original title: “Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales”
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
Original title: “Pfizer is a 2029 story but Q126 lays foundation for growth”
As Q1 earnings roll in, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least partly on novel assets for obesity.
Original title: “Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in”
In its latest biopharma pipeline report, Deloitte warned that the growing importance of a small pool of potential mega-blockbusters raises the risk of “significant value destruction from a single program failure.”
Original title: “Obesity ends oncology’s long reign as top contributor to biopharma pipeline value”
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or more infrequent dosing schedules.
Original title: “Amgen positions MariTide as potential ‘best monthly’ obesity drug”
The Food and Drug Administration (FDA) is establishing a public docket entitled "Obesity and Drug Dosing: Clinical Pharmacology Considerations." The Agency is soliciting input from interested persons on assessing the effect of obesity on drug pharmacokinetics and pharmacodynamics during drug (including biological product) development. These assessments could potentially inform whether obesity impacts the safety and effectiveness of the drug and dosing recommendations for obese patients.
Original title: “Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments”
Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.
Original title: “Lilly’s weight loss pill reaches brand new patients, even without full-court marketing press”
Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t have a chance for one key reason.
Original title: “Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act”
Boehringer Ingelheim reports significant reductions in weight
Original title: “Survodutide delivers 16.6% weight loss in major phase 3 obesity trial”
Clinical trial suggests semaglutide may help patients with alcohol use disorder and obesity.
Original title: “Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking ”
Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S.
Original title: “Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’”
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
Original title: “Boehringer dual-acting obesity shot hits mark in Phase 3 trial”
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.
Original title: “Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’”
integrated mirna mrna analysis reveals obesity driven regulatory networks in human visceral adipose tissue with and without type 2 diabetes
Original title: “Integrated miRNA-mRNA Analysis Reveals Obesity-Driven Regulatory Networks in Human Visceral Adipose Tissue With and Without Type 2 Diabetes.”
Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.
Original title: “Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool”